Evidence types
Clinical study articles covering observational research, trial reports, and human data relevant to Crohn's disease and IBD.
Page 16 of 21 · 1007 articles
The study suggests why a JAK1 inhibitor (filgotinib) may work better in some gut regions than others, offering a possible explanation for mixed clinical trial results in Crohn's disease. This could influence how future...
People with IBD and those on commonly used biologics may have different early T cell responses and faster waning after SARS-CoV-2 vaccination, which could affect timing or interpretation of immune monitoring and booster...
Extraintestinal manifestations (EIMs) can significantly affect people with IBD and may require multidisciplinary care. Knowing how often EIMs are documented and which patients are more likely to have them helps...
PROM completion is important for monitoring symptoms and disease control between visits. The study shows a single empowerment campaign produced a short‑term boost in PROM response but not sustained engagement,...
Researchers found distinct microbial and host molecular features in the appendices of children with IBD, which could help explain local immune activation and guide future studies of disease mechanisms or biomarkers.
New analytical tools for longitudinal microbiome data can reveal time-varying microbial signatures tied to Crohn's disease and ulcerative colitis. Identifying such biomarkers may eventually inform diagnosis, monitoring,...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Imaging. The original article is from Scandinavian Journal of Gastroenterology.
Personalizing adalimumab dosing could reduce underexposure, treatment failure, and immunogenicity for people with IBD. Validated popPK models are a key step toward reliable model-informed precision dosing in clinical...
IBD may involve small-vessel changes beyond the gut. If reproducible, retinal microvascular alterations detectable by OCTA could offer a non-invasive window into systemic microvascular involvement in IBD.
The study maps cellular and molecular programs that drive transformation of fissures into fistulas in Crohn's disease, pointing to early remodeling processes and specific molecular pathways that could be targeted to...
The study links symptom trajectories during the first year of biologic treatment to endoscopic remission, suggesting that week 20 symptom assessment may help predict long-term outcomes for people with UC on biologics.
The study suggests a herbal formula (H7F) may protect intestinal barrier function, modulate the gut microbiome, and suppress IL-17/NF-κB inflammation in a mouse colitis model—mechanisms relevant to IBD pathophysiology.
This study describes a new formulation of baicalein that improved drug solubility and oral absorption and showed benefit in a mouse model of ulcerative colitis—early-stage research that could inform future...
Improved methods for profiling mucosa-associated microbiota from routine archival FFPE biopsies could expand research using stored pediatric gut samples, helping identify microbiome features linked to Crohn’s disease and...
Patients and clinicians often face primary non-response to anti‑TNF therapy. Identifying reproducible mucosal gene-expression patterns linked to non-response helps explain biological differences between responders and...
Vulvar Crohn’s is a rare, often treatment-refractory manifestation. Reports that ustekinumab and risankizumab helped patients may expand options for people with cutaneous Crohn’s disease, especially after anti–TNF...
Researchers are exploring plant polyphenols and new oral delivery systems that might reduce gut inflammation and modify microbiota — findings in mice suggest potential but are not directly applicable to patients yet.
Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...
Patients and clinicians using vedolizumab for ulcerative colitis may expect early improvement, but a lack of remission at week 2 does not reliably predict long-term failure. Clear predictive metrics are needed before...
This survey shows IUS is increasingly recognized but underutilized in China due to limited training and varied perceptions across specialties; patients generally like IUS but many have safety concerns. Addressing...
If biologic availability, infusion capacity, or therapeutic drug monitoring are limited where you live, oral JAK inhibitors could offer a practical, effective alternative for moderate‑to‑severe IBD, according to this...
The study describes a new investigational bispecific antibody that reduced T-cell–driven inflammation in lab tests and a mouse colitis model, a potential new therapeutic strategy relevant to IBD research and future drug...
People with IBD (including those on TNF inhibitors) may benefit from research that explains why some patients don’t respond to anti-TNF drugs and that points to new biologic targets. Understanding cell types and...
Cure8 could only read part of this source from Intestinal Research, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Medications.
If confirmed, αvβ6 autoantibodies could help identify people at higher risk for ulcerative colitis and point to a new mechanism (blockade of epithelial TGF‑β activation) that contributes to mucosal inflammation.
The study presents a new oral NRF2 activator that reduced inflammation and tissue injury in a mouse model of ulcerative colitis, suggesting a potential novel therapeutic approach.
The study suggests chronic gut inflammation can cause measurable brain inflammation and neuronal dysfunction in an IBD model, and that creatine supplementation prevented those changes — a potential neuromodulatory...
If you have ulcerative colitis and cannot tolerate 5-ASA (mesalamine), this study suggests you may be at higher risk of progressing to difficult-to-treat disease, particularly if your intolerance fits an acute...
Cure8 could only read part of this source from Перспективи та інновації науки, so this card uses cautious topic tags instead of a full summary. It is tagged for Microbiome and Research and clinical trials.
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
For people with IBD who do not respond to standard biologic doses, escalating the dose appears common in routine care and was associated with better short-term remission rates and reduced healthcare use in this registry...
Decisions about having children are common and sometimes complex for women living with IBD. This study maps different motivation patterns and the factors linked to them, which could help clinicians tailor reproductive...
Children with autoimmune gastrointestinal diseases can have impaired bone health.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from The American Journal of...
If validated, epithelial CXCL1 could become a tissue biomarker that helps track remission specifically in ulcerative colitis and serve as a functional readout for epithelial-directed therapies tested in patient-derived...
Early company-reported clinical responses in special-access patients and planned Phase 2 trials could signal a new stem-cell therapy approach advancing for fistulising Crohn’s disease — a complication that can be hard to...
Noninvasive TUS can help detect small-bowel inflammation and stenosis in Crohn's disease with high specificity, potentially reducing the need for immediate invasive testing. However, its sensitivity varies by small-bowel...
Biosimilars can expand access to effective biologic treatment for people with IBD by reducing costs, but adoption barriers mean some patients may not benefit. Understanding evidence, practical concerns, and...
People with IBD and their clinicians often rely on MRI for monitoring disease; knowing that MRI techniques can also detect other bowel problems helps explain imaging choices and what radiologists may be looking for when...
The report suggests a probiotic (VSL#3TM) added to vedolizumab may speed or increase early response in ulcerative colitis, which could interest patients and clinicians seeking ways to improve biologic induction outcomes....
Cure8 found this source from Journal of gastroenterology and hepatology, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials....
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
This study suggests there are distinct molecular subtypes of perianal fistulizing Crohn’s disease, and some subtypes may be more likely to benefit from surgical repair while others have higher inflammatory burden and...
This NIH-funded project identifies probiotic metabolic pathways that protect gut barrier integrity in a diet-dependent way, which could explain mixed clinical trial results and point to biomarkers to select patients...
The project targets innate lymphocyte pathways that help control mucosal immunity in the gut and airway — mechanisms that can drive or restrain inflammation in IBD and related diseases. Better understanding may reveal...
This project explores how gut microbes and bile acids interact to shape immune cells in the ileum — a process that may affect inflammation in Crohn’s disease and other IBDs. Understanding these mechanisms could point to...
If surgeons can safely perform a primary bowel reconnection when they encounter an intra-abdominal abscess during Crohn surgery, some patients may avoid a temporary stoma and its associated morbidity.
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
